Alkermes PLC.
$46.85
Mkt Cap 7.87B
Biopharmaceutical company developing and marketing neuroscience medicines, including treatments for schizophrenia, bipolar disorder, and alcohol and opioid dependence.
alkermes.com ↗Summary by The Compound Family, based on the company’s own website
—
/100 Overall
Calculating score…
Running full analysis
Ready to value this company?
Run a full DCF model with Monte Carlo simulation.
Run DCF Valuation →
Run a full DCF model with Monte Carlo simulation.
Key Metrics
Loading full analysis…
REVENUE TTM
$1.75B
FCF TTM
$227.3M
P/FCF
34.6x
Running full 6-factor analysis…